Kivexa abacavir 600mg/lamivudine 300mg tablets

Prescribing Information

See Summary of Product Characteristics (SmPC) before prescribing.

Indications: HIV in adults, adolescents and children weighing at least 25 kg as part of combination therapy. Screen for HLA-B*5701 prior to use. **Dose:** one tablet daily with or without food. *Elderly:* No pharmacokinetic data in 65+ yrs. *Renal impairment*: Creatinine clearance <50ml/min: not recommended. *Hepatic impairment*: not recommended in moderate or severe hepatic impairment. Monitor closely in mild hepatic impairment. **Contraindications:** Hypersensitivity to any ingredient. **Special warnings/precautions:** Risk of hypersensitivity reactions (HSR). Do not initiate in patients who are HLA-B*5701 positive on screening or had previous suspected abacavir HSR. Stop Kivexa without delay if HSR suspected. Never re-introduce any abacavir-containing product after suspected HSR. Risks of virological failure, immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Use with cladribine, emtricitabine or high doses of co-trimoxazole not recommended. When possible, avoid chronic co-administration of sorbitol or other osmotic acting alcohols (see SmPC section 4.5). If unavoidable, consider more frequent viral load monitoring. Abacavir increased riociguat concentrations. Consider dose adjustment of riociguat. **Pregnancy/lactation:** Not recommended. Do not breast-feed. **Side effects:** See SmPC for full details. Hypersensitivity, GI disturbance**,** headache, anorexia, insomnia, rash, fever, lethargy, fatigue, malaise, arthralgia, muscle disorders, nasal symptoms, cough, alopecia, blood dyscrasias, rhabdomyolysis, lactic acidosis, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Basic NHS costs: £352.25 for 30 tablets. **MA number:** EU/1/04/298/002. **MA holder:** ViiV Healthcare BV, Van Asch van Wijckstraat 55H, 3811 LP Amersfoort, Netherlands.
Further information available from:
customercontactuk@gsk.com
Freephone 0800 221 441.

POM

Date of approval: January 2021 PI-0393v3

Adverse events should be reported. For the UK, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for **MHRA Yellowcard** in the **Google Play or Apple App store**. Adverse events should also be reported to GSK on 0800 221441.